全文获取类型
收费全文 | 2172篇 |
免费 | 75篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 38篇 |
妇产科学 | 20篇 |
基础医学 | 273篇 |
口腔科学 | 59篇 |
临床医学 | 126篇 |
内科学 | 577篇 |
皮肤病学 | 21篇 |
神经病学 | 132篇 |
特种医学 | 199篇 |
外科学 | 288篇 |
综合类 | 15篇 |
预防医学 | 130篇 |
眼科学 | 5篇 |
药学 | 156篇 |
中国医学 | 4篇 |
肿瘤学 | 197篇 |
出版年
2023年 | 8篇 |
2022年 | 26篇 |
2021年 | 52篇 |
2020年 | 25篇 |
2019年 | 44篇 |
2018年 | 57篇 |
2017年 | 34篇 |
2016年 | 35篇 |
2015年 | 32篇 |
2014年 | 76篇 |
2013年 | 80篇 |
2012年 | 135篇 |
2011年 | 114篇 |
2010年 | 78篇 |
2009年 | 72篇 |
2008年 | 103篇 |
2007年 | 126篇 |
2006年 | 108篇 |
2005年 | 107篇 |
2004年 | 86篇 |
2003年 | 89篇 |
2002年 | 68篇 |
2001年 | 52篇 |
2000年 | 55篇 |
1999年 | 39篇 |
1998年 | 24篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 22篇 |
1994年 | 14篇 |
1993年 | 7篇 |
1992年 | 33篇 |
1991年 | 30篇 |
1990年 | 32篇 |
1989年 | 45篇 |
1988年 | 20篇 |
1987年 | 32篇 |
1986年 | 26篇 |
1985年 | 29篇 |
1984年 | 20篇 |
1983年 | 16篇 |
1982年 | 10篇 |
1980年 | 14篇 |
1979年 | 24篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1975年 | 10篇 |
1973年 | 9篇 |
1972年 | 13篇 |
1967年 | 6篇 |
排序方式: 共有2251条查询结果,搜索用时 15 毫秒
1.
Migration of Kirschner (K) wires from the upper extremity joints has often been reported, but it is less common from the lower
extremities. In this report, we describe an 85-year-old man treated, during a hip replacement procedure, with a K-wire because
of a trochanteric fracture; after one year, the K-wire was found in the popliteal fossa. This report illustrates the first
case of K-wire migration in the popliteal area of the knee and suggests avoiding the use of free K-wires without any tension
banding. 相似文献
2.
M Strolin Benedetti E Pianezzola D Fraier M G Castelli P Dostert 《Xenobiotica; the fate of foreign compounds in biological systems》1991,21(4):473-480
1. The (13S)-dihydro derivative of idarubicin, (13S)-idarubicinol, is the major urinary metabolite of idarubicin in humans. Idarubicinol epimers were quantified by h.p.l.c. in urine from rats, mice, rabbits, dogs and man after i.v. administration of idarubicin, and in man after oral dosing. The (13R)- and (13S)-epimers of idarubicinol were determined in rat bile. 2. After i.v. injection of idarubicin. (13R)-idarubicinol was not detectable in mice and rabbit urine and no more than 0.5% of the dose was present in the urine of other species. In man, the proportion of (13R)-idarubicinol in total idarubicinol was similar after i.v. (4.1%) and oral (3.8-5.0%) administration of idarubicin; the same applies to rat bile and urine. 3. Reduction of idarubicin in vivo is dependent upon ketone reductases, and proceeds more stereoselectively than that of most ketones giving rise to the (13S)-epimer almost exclusively. The high stereospecificity in idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in idarubicin. 相似文献
3.
4.
Quantitative diagnostic performance of myocardial perfusion SPECT with attenuation correction in women. 总被引:1,自引:0,他引:1
Arik Wolak Piotr J Slomka Mathews B Fish Santiago Lorenzo Daniel S Berman Guido Germano 《Journal of nuclear medicine》2008,49(6):915-922
Attenuation correction (AC) for myocardial perfusion SPECT (MPS) had not been evaluated separately in women despite specific considerations in this group because of breast photon attenuation. We aimed to evaluate the performance of AC in women by using automated quantitative analysis of MPS to avoid any bias. METHODS: Consecutive female patients--134 with a low likelihood (LLk) of coronary artery disease (CAD) and 114 with coronary angiography performed within less than 3 mo of MPS--who were referred for rest-stress electrocardiography-gated 99mTc-sestamibi MPS with AC were considered. Imaging data were evaluated for contour quality control. An additional 50 LLk studies in women were used to create equivalent normal limits for studies with AC and with no correction (NC). An experienced technologist unaware of the angiography and other results performed the contour quality control. All other processing was performed in a fully automated manner. Quantitative analysis was performed with the Cedars-Sinai myocardial perfusion analysis package. All automated segmental analyses were performed with the 17-segment, 5-point American Heart Association model. Summed stress scores (SSS) of > or =3 were considered abnormal. RESULTS: CAD (> or =70% stenosis) was present in 69 of 114 patients (60%). The normalcy rates were 93% for both NC and AC studies. The SSS for patients with CAD and without CAD for NC versus AC were 10.0 +/- 9.0 (mean +/- SD) versus 10.2 +/- 8.5 and 1.6 +/- 2.3 versus 1.8 +/- 2.5, respectively; P was not significant (NS) for all comparisons of NC versus AC. The SSS for LLk patients for NC versus AC were 0.51 +/- 1.0 versus 0.6 +/- 1.1, respectively; P was NS. The specificity for both NC and AC was 73%. The sensitivities for NC and AC were 80% and 81%, respectively, and the accuracies for NC and AC were 77% and 78%, respectively; P was NS for both comparisons. CONCLUSION: There are no significant diagnostic differences between automated quantitative MPS analyses performed in studies processed with and without AC in women. 相似文献
5.
Conclusion We would like to stress that we do not necessarily consider AC for SPECT MPI to be unfeasible or unworthy of scientific pursuit;
indeed, a great deal of creative scientific effort has been poured into this area of investigation over the past 3 decades,
and much of it has contributed to a better understanding of the physics, as well as the clinical aspects, of our field. However,
the great variety of available AC hardware and software “flavors,” the historical pattern of commercial release of insufficiently
validated AC implementations, and the increasingly clouded health care reimbursement horizon may have created an environment
where the envisioned users of the technology have been desensitized and discouraged from expecting it to ever come to fruition
in a standardized, validated, and costeffective form.
It has been reported as recently as 2005 that the “entire base of SPECT cameras has only 5% of systems with attenuation correction.”8
Perhaps the reports of AC’s demise are exaggerated, but it certainly seems as if the people have spoken and, after readying
themselves for the wolf one too many times, have come to the conclusion that “the future (of AC) ain’t what it used to be”
. . .at least not yet. 相似文献
6.
A Bortolotti D Castelli D Verotta M Bonati 《European journal of drug metabolism and pharmacokinetics》1989,14(2):145-151
The pharmacokinetic and pharmacodynamic profiles of metoprolol were studied in adult male rabbits given 3.2 mg/kg i.v. before and during liver failure. The partition of metoprolol between blood cells and plasma averaged 1.14 in both conditions. Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively. With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure. Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1). Liver impairment did not affect the volume of distribution of the central compartment, the steady-state volume of distribution and the other intercompartmental rate constants. Although metoprolol was eliminated in the urine, the amount excreted was low (1.5% of the administered dose) in both conditions. The pharmacokinetic model was extended by an 'effect compartment', which has no influence on the predetermined mass of drug in the body, to analyse the relationship between heart rate fall and changes in metoprolol plasma concentrations. After drug administration, heart rate fell rapidly about 90 beats in both states. The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar. 相似文献
7.
8.
Endovascular repair for concomitant multilevel aortic disease. 总被引:2,自引:0,他引:2
Patrizio Castelli Roberto Caronno Gabriele Piffaretti Matteo Tozzi Chiara Lomazzi Domenico Laganà Gianpaolo Carrafiello Salvatore Cuffari 《European journal of cardio-thoracic surgery》2005,28(3):478-482
OBJECTIVE: Patients with multilevel aortic disease represent a small subgroup with the need for extensive surgical treatment at considerable risk. We present our experience of endovascular exclusion for simultaneous thoracic and abdominal aortic disease in four patients. METHODS: Between January 2002 and January 2005, four patients underwent endovascular repair for simultaneous thoracic and abdominal aortic disease. Mean age was 69+/-10 years (range, 60-81). Thoracic lesions included penetrating aortic ulcer (n=2, ruptured=1), atherosclerotic aneurysm (n=1), and chronic type B dissection (n=1). Abdominal aortic disease included atherosclerotic infrarenal (n=3) and juxtarenal (n=1) aortic aneurysms. Thoracic aortic stent-grafts had been the following: Excluder/TAG (n=3) or Talent (n=1) straight tube devices. Abdominal aortic stent-grafts used were as following: Excluder (n=3) or Zenith (n=1). All patients were followed-up with CT-angiography and chest X-rays 1, 4, 12 months after the procedure, and once per year thereafter. RESULTS: Stent-graft deployment was technically successful in all cases. Intraoperative mortality was not observed. Mean procedure time was 94+/-34 min (range, 70-145). Early postoperative complications occurred in one patient that developed acute renal failure but dialysis was not required. Mean hospitalisation was 8+/-5 days (range, 4-15). Late death occurred in one patient for an undetected ruptured thoracic type 1 endoleak. All three survivors are currently well 16.5 months (range, 3-36) after surgery. No neurological complications developed. CONCLUSION: Simultaneous abdominal and thoracic endovascular repair for multilevel aortic disease is feasible and could be a viable alternative in high-risk patients, who otherwise may not be suitable candidates for conventional repair. 相似文献
9.
D. M. F. Edwards C. Pellizzoni H. P. Breuel A. Berardi M. G. Castelli E. Frigerio I. Poggesi M. Rocchetti A. Dubini M. Strolin Benedetti 《Biopharmaceutics & drug disposition》1995,16(6):443-460
The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4 and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed therapeutic tablet formulation (4mg). Kinetic analysis was based on HPLC assay of reboxetine in plasma and urine collected up to 72 h after each administration. Plasma levels indicated a rapid absorption (tmax?2h) and an elimination half-life of about 13 h. Clearance and volume of distribution were modest (ratios to bioavailability: CL/F?29 mL min?1; Vz/F?32L); urinary excretion was ~9% of dose, corresponding to a renal clearance of only 3 mL min?1 (a value consistent with the rate of glomerular filtration of unbound drug). In vitro, binding to plasma proteins, estimated from radioactivity levels following dialysis of 14C-labelled reboxetine, appeared to be dominated by α1-acid glycoprotein without marked saturation up to plasma concentrations of over 500 ng mL?1 (2.8–3.1% unbound with human plasma from three additional volunteers; 1.8–2.0% for 2gL?1 orosomucoid α1-acid glycoprotein, and 46.4–47.4% for 40 gL?1 albumin), whilst the mean Cmax in the current study was much lower (164 ng mL?1 after a 5 mg dose). 相似文献
10.